#abcellera

[kramlabs]

“Finding” antibodies in a human (after synthetic exosome injection) vs designing antibodies in a lab

:

*george Webb…. Not sure what to think.

#abcellera #peter thiel #robert malone #mrna #exosomes #antibodies #carl Hansen #everything is fucking managed #epivax #JC on a bike #Paul cottrell

[usnewsper-business]

Biotech Company AbCellera Faces Layoffs Amidst Industry Slump: What Does This Mean for Antibody Therapies? #abcellera #antibodytherapies #biotechindustry #biotechnologycompany #layoffs

#Business #abcellera #antibodytherapies #biotechindustry #biotechnologycompany #layoffs

[faultfalha]

The scientists at AbCellera Biologics are confident in their promising new platform, but they advise a watch-and-wait approach for the time being. The platform has the potential to revolutionize the treatment of diseases, but only further research will tell if that potential can be realized. The company is confident in their technology, but they don't want to make any rash promises. For now, they are content to let their research speak for itself.

#ABCL #Stephen Ayers #fault

[marketresearch456]

[gjupdates]

AbCellera Biologics (ABCL) Q4 2022 Earnings Call Transcript

[ad_1] Image source: The Motley Fool. AbCellera Biologics (ABCL -7.30%)Q4 2022 Earnings CallFeb 21, 2023, 5:00 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good afternoon. And welcome to AbCellera’s full year 2022 business update conference call. My name is Daniel, and I will facilitate the audio portion of today’s interactive…

View On WordPress

[moneygigs]

AbCellera Biologics (ABCL) Q4 2022 Earnings Call Transcript

Image source: The Motley Fool. AbCellera Biologics (ABCL -7.30%)Q4 2022 Earnings CallFeb 21, 2023, 5:00 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good afternoon. And welcome to AbCellera’s full year 2022 business update conference call. My name is Daniel, and I will facilitate the audio portion of today’s interactive broadcast.…

View On WordPress

[democracyin-news]

I want to buy more Marvell Technology

I want to buy more Marvell Technology

Marvell Technology Inc: “They are the best when it comes to 5G, the best in high-performance computing. But remember, those things have fallen out of favor right now. … I’d like to buy more [for the Charitable Trust.] That’s the way to go.” Stem Inc: “It got very, very high. We moved away from companies that don’t make money. … We’re not recommending stocks that don’t [make] money.” AbCellera…

View On WordPress

[fromsciencetopharma]

Lilly partner AbCellera adds bispecifics platform to antibody arsenal #AbCellera #bispecifics #EliLilly “Canada’s AbCellera is already a go-to partner for big biopharma antibody discovery efforts, inking deals with the likes of Merck, Pfizer, GlaxoSmithKline and Eli Lilly. Now, it’s adding another tool to its offerings: a bispecifics platform that can combine any two of the antibodies it discovers. AbCellera picked up the platform, dubbed OrthoMab, from Dualogics for an undisclosed amount. And that’s not all—the company also hired Tim Jacobs, Ph.D., who led multiple bispecific antibody programs at Dualogics as its chief technology officer. The acquisition comes after the company raised $105 million in venture capital to boost its antibody work and invest in technologies to complement its discovery engine. Under the deal, AbCellera has full rights to the OrthoMab technology, while Dualogics holds onto the rights to develop its own programs based on the platform, as well as finish out the partnerships it’s already struck.” https://www.instagram.com/p/CEN2ilQDf-j/?igshid=i7j47lxv52n

#abcellera #bispecifics #elililly

[pavlebasic]

Bil Gejts: Prva vakcina možda neće biti savršena, a dok se ne pojavi - tu su monoklonska antitela

Bil Gejts: Prva vakcina možda neće biti savršena, a dok se ne pojavi – tu su monoklonska antitela

Gejts je na svom blogu izrazio mišljenje da bi prve vakcine mogle tek da „premoste jaz“ (stop-gap) pre no što one „prave“ postanu dostupne – pre svega bogatim zemljama.

Iako je optimističan u pogledu roka za izlazak prve vakcine protiv korone (početkom sledeće godine), osnivač Microsofta i filantrop koji podržava nekoliko…

View On WordPress

#AbCellera #alergije #Amgen #antitela #AstraZeneca #Australija #bezbednost #Bil Gejts #biohemičar #bioreaktori #Blumberg #bolesti #budućnost #ciljani #CoVPN #delovanje #diskusija #DNK #dobrovoljac #doza #Džonson i Džonson #efikasnost #Eli Lilly #Entoni Fauči #farmaceutski #faza #Genentech #genetski #GlaxoSmithKline #hospitalizovani

[medicircle-blog]

#AbCellera and #EliLilly Agreed to Co-develop Antibody Products to Fight #COVID19 #medicircle https://bit.ly/2Qd8xAw https://www.instagram.com/p/B9rDLOgJIuw/?igshid=1ce8mo6dn6k6f

#abcellera #elililly #covid19 #medicircle

[kramlabs]

:

:

:

DARPA ADEPT vs ARMY (USAMRIID) ADEPT:

#spars #fort detrick #live exercise #lock step #sage hana #AbCellera #sv40

[usnewsper-business]

Biotech Company AbCellera Faces Layoffs Amidst Industry Slump: What Does This Mean for Antibody Therapies? #abcellera #antibodytherapies #biotechindustry #biotechnologycompany #layoffs

#Business #abcellera #antibodytherapies #biotechindustry #biotechnologycompany #layoffs

[socialnetlive]

#covid19helpnow.org #COVID19 #COVID-19 #coronavirus

[chikuri]

米国防総省の国防高等研究計画局（DARPA）は、致死率が高い新型ウイルスに対する抗体を60日以内に特定・生成することを目標に、2年前に「パンデミック防止プラットフォーム（P3）」プログラムを立ち上げている。デューク大学とヴァンダービルト大学のメディカルスクールから研究者を募り、AbCelleraと製薬大手のアストラゼネカにも協力を求めた。 いま中国で猛威を振るっている新型コロナウイルスのようなアウトブレイクに備えて、P3プログラムの科学者は、SARS（重症急性呼吸器症候群）およびMERS（中東呼吸器症候群）の原因となるウイルスを使用して試験を実施した。どちらもコロナウイルス科のウイルスで、COVID-19と密接に関連している。 研究者はこの2種類のコロナウイルスの抗体を分離したあと、遺伝子コードを特定し、それを基に抗体を大量生産する。患者に直接注射することで、感染したコロナウイルスに対して即座に抵抗力を与える抗体薬を開発することが目標だ。 「わたしたちは患者の血液を採取し、抗体を特定します。これを素早く実施するのです」と、DARPAのバイオロジカルテクノロジー研究室プログラムマネージャーのエイミー・ジェンキンスは説明する。同研究室はAbCelleraの研究に4年間で3,500万ドル（約38億4,000万円）の資金を支援している。 「抗体を分離できたら、まだ症状の出ていない人にその抗体を与えることができます。抗体はワクチンと同じように感染を防ぎます。違いは、ワクチンの効果は長く持続する点です。わたしたちはワクチンほど効果が長く続かなくても、いますぐ免疫力をつけられる治療法を目指しています」

新型コロナウイルスを止めるべく、米国が「抗体」の開発を急いでいる｜WIRED.jp

[gjupdates]

AbCellera Biologics Inc. 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:ABCL)

[ad_1] This article was written by Follow Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments.…

View On WordPress

[moneygigs]

AbCellera Biologics Inc. 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:ABCL)

This article was written by Follow Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA…

View On WordPress